{"disease":{"id":"myelokathexis","name":"myelokathexis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"mavorixafor","indication_name":"myelokathexis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xolremdi","generic_name":"MAVORIXAFOR","company_name":"X4 Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"CXC Chemokine Receptor 4 Antagonist [EPC]","quality_score":54,"revenue":null,"mechanism":"Xolremdi blocks the CXC Chemokine Receptor 4 to treat WHIM syndrome."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00967785","title":"A Phase I Study of Mozobil in the Treatment of Patients With WHIMS","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02231879","title":"Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}